Jul 2 |
COCP: CC-42344 Shows In Vitro Activity Against Avian Influenza A (H5N1)…
|
Jun 20 |
New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows
|
Jun 7 |
Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy?
|
May 16 |
COCP: Enrollment Complete in Phase 2a Human Challenge Trial of CC-42344…
|
May 13 |
Cocrystal Pharma GAAP EPS of -$0.39 beats by $0.15
|
May 13 |
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
|
May 1 |
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
|
Apr 23 |
COCP: Topline Data for Influenza A and Dual Coronavirus/Norovirus Programs Expected in 2024; Model Revision Leads to Valuation of $6 Per Share…
|
Mar 28 |
Cocrystal Pharma GAAP EPS of -$1.87
|
Mar 28 |
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
|